Tuesday, 20 Mar 2018

You are here

Ibuprofen’s Anti-androgenic Effect May Result in Hypogonadism in Males

PNAS reports use of ibuprofen by males may result in antiandrogen effects that may contribute to adult male reproductive problems.

Young men exposed to ibuprofen show changes of “compensated hypogonadism," a condition usually seen among elderly men and associated with reproductive and physical disorders. In the men, luteinizing hormone (LH) and ibuprofen plasma levels were positively correlated, and the testosterone/LH ratio decreased.

Researchers used a combination of a randomized, controlled clinical trial and ex vivo and in vitro approaches, and found a univocal depression of testicular function, including testosterone production, after use of over-the-counter ibuprofen.

Also, ibuprofen use results in selective transcriptional repression of endocrine cells in the human testis. This repression results in the elevation of the stimulatory pituitary hormones, resulting in a state of compensated hypogonadism.

Thes findings show ibuprofen alters the endocrine system via selective transcriptional repression in the human testes, thereby inducing compensated hypogonadism.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Repeat Malignancy Unlikely with Biologic Therapy

Research from the Danish biologics registry shows that the use of a biologic in patients with a history of a primary cancer does not increase the risk of a second malignant neoplasm (SMN) or mortality in rheumatoid arthritis (RA) patients.

They analyzed 15,286 RA patients in the DANBIO Register between 2000–2011 and found 1678 with a primary cancer.  The majority (1203) did not use biologics after. 

Opportunistic Infections in RA Rare with Biologics

The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis has studied nearly 20,000 patients and observed that there is no substantially different risk of opportunistic infections between different biologics. 

Biologics in Pregnancy: Are They Safe?

Exposure to biologic therapies among women with autoimmune diseases was not associated with increased risks of preterm delivery or having small for gestational age babies, a population-based Canadian study found.

DSB – Safety Updates & Drug Shortages – March 2018

This edition of RheumNow's Drug Safey Bulletin includes drug safety news, FDA updates, FDA safety labeling changes and reported drug shortages. 

Steroid Use During Rheumatoid Pregnancies

Pregnant women (n=254) with rheumatoid arthritis who enrolled in the MotherToBaby Autoimmune Diseases in Pregnancy Study  and who were taking oral glucocorticoids were studied.